Free Trial
NASDAQ:TRML

Tourmaline Bio (TRML) Stock Price, News & Analysis

Tourmaline Bio logo
$17.21 +0.96 (+5.91%)
As of 04:00 PM Eastern

About Tourmaline Bio Stock (NASDAQ:TRML)

Key Stats

Today's Range
$15.79
$17.70
50-Day Range
$12.10
$18.80
52-Week Range
$11.56
$29.79
Volume
358,144 shs
Average Volume
268,833 shs
Market Capitalization
$442.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.33
Consensus Rating
Buy

Company Overview

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Tourmaline Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

TRML MarketRank™: 

Tourmaline Bio scored higher than 50% of companies evaluated by MarketBeat, and ranked 708th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tourmaline Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tourmaline Bio has only been the subject of 4 research reports in the past 90 days.

  • Read more about Tourmaline Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tourmaline Bio is -6.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tourmaline Bio is -6.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tourmaline Bio has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Tourmaline Bio's valuation and earnings.
  • Percentage of Shares Shorted

    19.08% of the float of Tourmaline Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Tourmaline Bio has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Tourmaline Bio has recently decreased by 5.26%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Tourmaline Bio does not currently pay a dividend.

  • Dividend Growth

    Tourmaline Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.08% of the float of Tourmaline Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Tourmaline Bio has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Tourmaline Bio has recently decreased by 5.26%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Tourmaline Bio has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Tourmaline Bio this week, compared to 3 articles on an average week.
  • Search Interest

    1 people have searched for TRML on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tourmaline Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.02% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tourmaline Bio's insider trading history.
Receive TRML Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tourmaline Bio and its competitors with MarketBeat's FREE daily newsletter.

TRML Stock News Headlines

Chardan Capital Forecasts Tourmaline Bio FY2025 Earnings
China’s next move could destroy U.S. tech
The U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs China for growth. Nvidia depends on the global chip chain. The MAG 7 have already bled $3.4 trillion — and the next phase could be worse. But while panic sets in, there's a small group of investors pulling in reliable, high-yield monthly income…
Tourmaline Bio initiated with a Buy at Chardan
Tourmaline Bio (TRML) Gets a Buy from Chardan Capital
See More Headlines

TRML Stock Analysis - Frequently Asked Questions

Tourmaline Bio's stock was trading at $20.28 at the beginning of 2025. Since then, TRML shares have decreased by 13.5% and is now trading at $17.54.
View the best growth stocks for 2025 here
.

Tourmaline Bio, Inc. (NASDAQ:TRML) posted its earnings results on Thursday, March, 13th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.05. The business had revenue of $0.04 million for the quarter.

Tourmaline Bio's top institutional investors include SG Americas Securities LLC (0.14%), Rhumbline Advisers (0.13%) and GAMMA Investing LLC (0.03%). Insiders that own company stock include Mark Mcdade, Parvinder Thiara and Sandeep Chidambar Kulkarni.
View institutional ownership trends
.

Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
3/13/2025
Today
4/30/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRML
Previous Symbol
NASDAQ:TRML
Web
N/A
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$49.33
High Stock Price Target
$70.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+181.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-42,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$10.08 per share
Price / Book
1.74

Miscellaneous

Free Float
22,817,000
Market Cap
$450.51 million
Optionable
Optionable
Beta
2.14
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:TRML) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners